What is the target price of Gland Pharma share in 2024?
| Year | Share price (Bear Case) | Share Price (Bull Case) |
|---|---|---|
| 2022 | 1227 | 3681 |
| 2023 | 1472 | 4417 |
| 2024 | 1767 | 5300 |
| 2025 | 2120 | 6360 |
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gland Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Given the gradual improvement in the core business, the brokerage house has reiterated its Buy rating on Gland Pharma shares with a target price of ₹2,470 apiece. The pharma stock is down more than 52% in 2022 (YTD) so far.
Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. The issue is priced at ₹1490 to ₹1500 per share.
View 7 reports from 3 analysts offering long term price targets for Gland Pharma Ltd.. Gland Pharma Ltd. has an average target of 2323.33. The consensus estimate represents an upside of 118.03% from the last price of 1065.60.
| Date | Close | High |
|---|---|---|
| 19 Fri May 2023 | 440.45 | 447.70 |
| 18 Thu May 2023 | 421.75 | 428.00 |
| 17 Wed May 2023 | 418.05 | 421.55 |
| 16 Tue May 2023 | 419.45 | 422.00 |
Should you buy Gland Pharma? Speaking on the stock price outlook, Rahul Ghose, Founder & CEO–Hedged, an algorithm-powered advisory platform said “The gland pharma stock is currently near its all-time low and the previous support area around INR 1170 level, which is not a strong reason to initiate a buy on it.
...
Market share of top 10 national pharmaceutical markets worldwide in 2021.
Plant shutdowns, a decline in the B2C business in India, and volatility in the Rest of World tender business hurt Gland Pharma's earnings in the March quarter, which missed estimates on all fronts. The company reported its fourth straight quarter of decline in revenue and profit.
Gland Pharma Ltd. has not split the face value of the share since Jan 1, 2000. VOTE: Is Gland Pharma Ltd. worth buying?
Who bought Gland Pharma?
Fosun Pharma acquired a 74 per cent stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co.
| S.No. | Top Stocks |
|---|---|
| 1. | Sun Pharmaceutical Industries |
| 2. | Divi's Laboratories |
| 3. | Cipla |
| 4. | Dr. Reddy's Laboratories |
Pharmaceutical Drug, LIPITOR created, marketed, and sold by PFIZER corporation is regarded to be the most profitable drug in the pharma field. While it enjoyed patent protection, the drug generated over $131 billion in sales. Lipitor was released in 1997, the year which saw the FDA allow targeted drug ads.
- Cullinan Oncology, Inc. (NASDAQ:CGEM)
- iTeos Therapeutics, Inc. (NASDAQ:ITOS)
- Innoviva, Inc. (NASDAQ:INVA)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
- Immatics N.V. (NASDAQ:IMTX)
- Novartis AG (NYSE:NVS)
- Syneos Health, Inc. (NASDAQ:SYNH)
The ability of pharmaceutical companies to shrug off economic downturns is one big reason investors often flock to them during bear markets. Not only do large-cap pharma companies offer shareholders a respite from marketwide volatility, but they also generally come with top-shelf dividend programs.
Amrutanjan Health Care Ltd. Anuh Pharma Ltd. Auro Laboratories Ltd. Aurobindo Pharma Ltd.
| High | $75.00 |
|---|---|
| Low | $38.00 |
| Average | $46.94 |
| Current Price | $36.48 |
What is the share price target of Sun Pharma for 2025? The share price target of Sun Pharma for 2025 might be around ₹2,342.63.
| Company | Forward Sales Growth Next Year |
|---|---|
| Alphabet (GOOG, GOOGL) | +11.8% |
| Eli Lilly (LLY) | +19.4% |
| Match (MTCH) | +13.0% |
| Progressive (PGR) | +10.9% |
| Stock | YTD Total Returns Through May 17 |
|---|---|
| Amazon.com Inc. (AMZN) | 37.5% |
| Walt Disney Co. (DIS) | 6.8% |
| PayPal Holdings Inc. (PYPL) | -13.7% |
| EOG Resources Inc. (EOG) | -12.5% |
What is the target price for good year shares in 2025?
| Date | Opening price | Maximum price |
|---|---|---|
| May 2025 | Open: 1345.298 | Max: 1345.298 |
| June 2025 | Open: 1336.456 | Max: 1366.391 |
| July 2025 | Open: 1367.202 | Max: 1390.082 |
| August 2025 | Open: 1387.970 | Max: 1387.970 |
Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), and Merck & Co., Inc. (NYSE:MRK) are some other best dividend stocks from the pharma sector on our list.
Gland Pharma Limited Reviews FAQs
Gland Pharma Limited has an overall rating of 3.8 out of 5, based on over 82 reviews left anonymously by employees. 93% of employees would recommend working at Gland Pharma Limited to a friend and 74% have a positive outlook for the business.
Gland Pharma on Wednesday reported a consolidated PAT of Rs 241 crore for the September quarter of FY 2023 against Rs 302 crore YoY. Consolidated revenue from operations stood at Rs 1,044 crore as against Rs 1,080 crore in the same quarter a year ago.
The “Big Three”—AmerisourceBergen, Cardinal Health, and McKesson—dominate the distribution of products in the wholesale (primary care) and generic space, and these companies are increasingly distributing specialty therapies.
| Rank | Country | Value of Pharmaceutical Market (in millions of $) |
|---|---|---|
| 1 | USA | 339,694 |
| 2 | Japan | 94,025 |
| 3 | China | 86,774 |
| 4 | Germany | 45,828 |
1. Pfizer Inc (US) Pfizer is the world's largest research-based pharmaceutical company. Its research headquarters are located in Groton, Connecticut, America.
About. Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 17,550.52 Crore) operating in Pharmaceuticals sector. Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Export Incentives for the year ending 31-Mar-2022.
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block.
About Gland Pharma
We have a professional management team and one of our Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.
Who owns the biggest pharmacy?
The largest pharmaceutical company in the U.S. is Pfizer, with a revenue of $100.33 billion. As of 2021, the U.S. pharmaceutical industry has a market size of $560 billion.
Gland Pharma has 3,961 employees. View the comprehensive list of Gland Pharma employees, their locations, business contact details and key personnel.
We are focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. We are present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings.
Fosun Pharma 'massively' fakes API production data and bribes regulators, whistleblower says. After Zhejiang Huahai Pharmaceutical's tainted valsartan API and Changchun Changsheng Life Sciences' fabricated vaccine production data exposé, China's drug industry could be dealing with another major manufacturing scandal.
Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world.
- Sun Pharmaceutical Industries Ltd. Sun Pharma is India's biggest drugmaker and has a market cap north of Rs 2 lakh crore. ...
- Divi's Laboratories Ltd. ...
- Dr Reddy's Laboratories Ltd. ...
- Cipla Ltd. ...
- Biocon Ltd. ...
- Apollo Hospitals. ...
- Growth plus value. ...
- High profit margin.
| Symbol | Company Name | 1-Year Return |
|---|---|---|
| BIIB | Biogen Inc. | 44.59% |
| GILD | Gilead Sciences Inc. | 33.54% |
| VRTX | Vertex Pharmaceuticals Inc. | 26.84% |
| REGN | Regeneron Pharmaceuticals Inc. | 18.68% |
- #1 Marksans Pharma.
- #2 Morepen Laboratories.
- #3 Bliss GVS Pharma.
- #4 Alembic.
- #5 SMS Pharma.
| Date | Opening price | Maximum price |
|---|---|---|
| Earum Pharmaceuticals Ltd. Stock Price Forecast for 2025 | ||
| January 2025 | Open: 205.641 | Max: 208.113 |
| February 2025 | Open: 208.228 | Max: 210.326 |
| March 2025 | Open: 210.442 | Max: 212.655 |
AMD stock price stood at $95.06
According to the latest long-term forecast, AMD price will hit $110 by the end of 2023 and then $150 by the end of 2024. AMD will rise to $200 within the year of 2026, $250 in 2027, $300 in 2030 and $350 in 2034.
What is the target price for BIIB stock?
| High | $398.00 |
|---|---|
| Median | $340.00 |
| Low | $263.00 |
| Average | $332.04 |
| Current Price | $313.57 |
- The all-time high Target stock closing price was 257.58 on November 16, 2021.
- The Target 52-week high stock price is 183.89, which is 20.8% above the current share price.
Pfizer stock price stood at $36.77
According to the latest long-term forecast, Pfizer price will hit $40 by the middle of 2023 and then $55 by the end of 2024. Pfizer will rise to $65 within the year of 2025, $70 in 2026, $75 in 2027, $85 in 2028, $90 in 2030, $95 in 2031, $100 in 2032 and $110 in 2034.
| Date | Open | High |
|---|---|---|
| May 19, 2023 | 169.99 | 171.65 |
| May 18, 2023 | 167.83 | 168.69 |
| May 17, 2023 | 168.48 | 168.52 |
| May 16, 2023 | 166.92 | 168.70 |
| # | Name | Price |
|---|---|---|
| 1 | Eli Lilly 1LLY | $436.65 0.49% |
| 2 | Johnson & Johnson 2JNJ | $159.34 0.13% |
| 3 | Novo Nordisk 3NVO | $167.66 1.04% |
| 4 | Merck 4MRK | $116.08 0.25% |
Management said during the company's 2022 investor day in June last year that it expects long-term annual revenue growth of 20%. Assuming AMD's top line grows at an annual pace of even 15% over the next five years, revenue could jump to $47 billion at the end of the forecast period.
By the end of 2030, NVDA is predicted to hit $1,195, a 426% increase from today to the year's end if the forecast is realized. Nvidia has been assigned a recommendation of 'buy' by most analysts working on Wall Street.
So, AMD's market capitalization could hit nearly $2 trillion in 2030 considering the potential upside that it could deliver, which means that its valuation is unlikely to exceed Apple's as the latter is worth close to $3 trillion right now.
| High Lows | |
|---|---|
| 52 Week High (Unadjusted) | 1.27 (09/05/2022) |
| 52 Week Low (Unadjusted) | 0.53 (28/03/2023) |
| Month H/L | 0.75 / 0.65 |
| Week H/L | 0.73 / 0.69 |
| Date | Opening price | Change |
|---|---|---|
| November 2023 | Open: 0.817 | Change: 0.39 % ▲ |
| December 2023 | Open: 0.819 | Change: 2.35 % ▲ |
| Biogen Pharmachem Industries Ltd. Stock Price Forecast for 2024 | ||
| January 2024 | Open: 0.846 | Change: 9.01 % ▲ |
Should I buy BIIB stock?
The financial health and growth prospects of BIIB, demonstrate its potential to outperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
- U.S. Bancorp USB.
- Taiwan Semiconductor Manufacturing TSM.
- GSK PLC GSK.
- Wells Fargo WFC.
- Roche Holding RHHBY.
- Comcast CMCSA.
- International Flavors & Fragrances IFF.
- Anheuser-Busch InBev BUD.
| High | $110.00 |
|---|---|
| Median | $80.50 |
| Low | $62.00 |
| Average | $82.50 |
| Current Price | $72.46 |
On average, Wall Street analysts predict that Best Buy Co's share price could reach $83.00 by May 11, 2024. The average Best Buy Co stock price prediction forecasts a potential upside of 15.71% from the current BBY share price of $71.73.
